No Obvious Role for Suspicious Oral Pathogens in Arthritis Development

Poerwati S. Rahajoe 1,2, Menke J. de Smit 3,5,*, Elisabeth Raveling-Eelsing 3, Marines du Teil Espina 5, Tim Stobernack 5, Paola Lisotto 2,*, Hermie J. M. Harmsen 5, Jan Maarten van Dijl 3,*, Nyoman Kertia 6, Arjan Vissink 2,5,6 and Johanna Westra 3,6

Abstract: A particular role for *Porphyromonas gingivalis* (Pg) and *Aggregatibacter actinomycetemcomitans* (Aa) has been suggested in periodontitis and rheumatoid arthritis (RA), as these bacteria could initiate the formation of rheumatoid factor (RF) and anticitrullinated protein autoantibodies (ACPA). We assessed whether serum antibodies against Pg and Aa in RA patients and non-RA controls reflect the subgingival presence of Pg and Aa, and evaluated the relationship of these antibodies to the severity of periodontal inflammation and RA-specific serum autoantibodies. In 70 Indonesian RA patients and 70 non-RA controls, the subgingival presence of Pg and Aa was assessed by bacterial 16S rRNA gene sequencing, and serum IgG levels specific for Pg and Aa were determined. In parallel, serum levels of ACPA (ACPA:IgG, IgA) and RF (RF:IgM, IgA) were measured. The extent of periodontal inflammation was assessed by the periodontal inflamed surface area. In both RA patients and the controls, the presence of subgingival Pg and Aa was comparable, anti-Pg and anti-Aa antibody levels were associated with the subgingival presence of Pg and Aa, and anti-Pg did not correlate with ACPA or RF levels. The subgingival Pg and Aa were not related to RA. No noteworthy correlation was detected between the antibodies against Pg and Aa, and RA-specific autoantibodies.

Keywords: rheumatoid arthritis; periodontitis; *Aggregatibacter actinomycetemcomitans*; *Porphyromonas gingivalis*; rheumatoid factor; anticitrullinated protein antibodies; risk factors

1. Introduction

Periodontitis is epidemiologically associated with rheumatoid arthritis (RA), a chronic autoimmune disease characterized by inflammation of the joints, causing pain, bone damage, and disability, although the directionality of this relationship is not known [1]. The development of RA is a multistep process in which early phases are characterized by the presence of genetic and environmental risk factors and the systemic autoimmunity associated with RA, such as rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) [2]. Periodontitis shares genetic and environmental risk factors with RA, and periodontitis by itself has been regarded as a risk factor for RA development [3,4].
RA was hypothesized to start at chronically inflamed mucosal surfaces, as encountered in periodontitis [5]. In addition to chronic mucosal inflammation, infection with specific periodontal pathogens has been implicated in the initiation of RA. Much attention has been focused on *Porphyromonas gingivalis* (Pg), which secretes a peptidyl arginine deiminase enzyme (PAD) that can citrullinate bacterial and human proteins [6–8]. Rosenstein et al. [3] suggested that PAD-induced antigens lead to the production of RF-containing immune complexes. In addition, this unique characteristic of Pg led to the hypothesis that the breakdown of tolerance against citrullinated proteins and the formation of ACPA are initiated by PAD-dependent citrullination [6,9]. Periodontal infection by *Aggregatibacter actinomycetemcomitans* (Aa) has also been implicated in the initiation of autoimmunity in RA. A secreted leukotoxin of Aa (LtxA) was shown to dysregulate activation of the human PAD enzymes in host neutrophils, leading to the release of hypercitrullinated proteins that mimic the repertoire of citrullinated antigens found in the RA joint [10].

A recent meta-analysis concluded that periodontitis may represent a risk factor for RA because of the genetic risks, bacterial infection, and proinflammatory profile shared between both diseases, although there was considerable heterogeneity among studies [11]. The reasons for conflicting epidemiological findings might be caused by the nonspecific classification criteria applied to periodontitis, the size of the patient cohorts used in the studies, and the lack of data regarding confounding factors and treatments [11]. It was suggested that, for a better understanding of the relationship between periodontitis and RA, retrospective studies without clinical periodontitis measurements could instead focus on the presence of Pg infection, which may be estimated objectively by measuring antibody levels [9]. Furthermore, it was suggested that anti-Pg antibodies might have predictive value for arthritis development [12]. The major objective of our study was to evaluate the extent to which serum antibodies against Pg and Aa in RA patients and non-RA controls (NC) reflect the subgingival presence of Pg and Aa, and to assess whether antibodies against these two pathogens can be related to the severity of periodontal inflammation and the levels of serum autoantibodies specific for RA. The results of this study reveal that, in our Indonesian study population, there was no obvious role of suspicious oral pathogens in arthritis development. Serum antibody levels against Pg and Aa indeed reflect subgingival infection with these oral pathogens; however, they cannot be used as a surrogate measure for periodontitis.

2. Materials and Methods

2.1. Patients

The included subjects were derived from a previously described Indonesian cohort [13]. In 70 RA patients and 70 NC with known periodontal status, the subgingival presence of Pg and Aa 16S rRNA was determined, as well as the serum antibodies to these periodontal pathogens (anti-Pg and anti-Aa). The inflammatory burden of periodontitis was assessed by the periodontal inflamed surface area (PISA) [14]. Two RA patients from the original cohort were excluded because of the absence of microbiological data. The non-RA controls were matched to the RA patients according to age, sex, smoking status, and number (Table 1). The factors that can influence the PISA are systemic disease, pregnancy, or the use of medication. Patients with diabetes, cardiovascular disease with anticoagulant medication, or that exhibited the presence of nonoral infection or malignancy, or patients that used antibiotics <3 months prior the study were excluded. Pregnancy, including a 6-month post-partum period, and breastfeeding were also exclusion criteria. Medication for hypertension was recorded. The 6 patients using calcium channel blockers all had a low percentage of sites with bleeding on probing (range 0–9.4%). Other medication for hypertension that can cause gingival overgrowth (such as nifedipine) was not used.
Table 1. Characteristics of patients with rheumatoid arthritis (RA) and non-RA controls (NC) modified after [13].

| Subject Characteristics | RA (n = 70) | NC (n = 70) | p Value |
|-------------------------|------------|------------|---------|
| Age (mean, SD)          | 47.3 (11.1)| 46.7 (11.9)| 0.753   |
| Female (n) (%)           | 62 (88.6) | 62 (88.6) | 1       |
| Current smoking (n) (%)  | 2 (2.9)   | 1 (1.4)   | 1       |
| Never smoking (n) (%)    | 7 (10.00) | 6 (8.6)   | 1       |
| Co-morbidity (n) (%)     |            |            |         |
| Asthma (+bronchodilator) | 0 (0)     | 3 (4.3)   | 0.245   |
| Hypertension (+medication)| 7 (10.0) | 4 (5.7)   | 0.532   |
| Medication for hypertension, also combinations (n): | | | |
| Calcium channel blocker  | 4          | 2          |         |
| ACE inhibitor            | 2          | 2          |         |
| Angiotensin receptor blocker | 2        | 0          |         |
| RA patient characteristics: | | | |
| Disease duration in months (median, IQR) | 24 (6–48) |          |         |
| DAS28 (mean, SD)         | 5.1 (1.1) |            |         |
| Disease remission (DAS28 < 2.6) (n) (%) | 0 (0) | 0 (0) | 1 |
| Low activity (DAS28 ≥ 2.6 < 3.2) (n) (%) | 3 (4.3) | 4 (5.7) | 1 |
| Moderate activity (DAS28 ≥ 3.2 < 5.1) (n) (%) | 25 (35.7) | 42 (60.0) | 1 |
| High activity (DAS28 ≥ 5.1) (n) (%) | 42 (60.0) | 42 (60.0) | 1 |
| Medication for RA (n) (%), also combinations: | | | |
| None                    | 8 (11.4)  |            |         |
| Herbal                  | 5 (7.1)   |            |         |
| NSAID                   | 44 (62.9) |            |         |
| Steroid                 | 55 (78.6) |            |         |
| DMARD total             | 40 (57.1) |            |         |
| DMARD specific (n):     |            |            |         |
| Methotrexate            | 32         |            |         |
| Leflunomide             | 2          |            |         |
| Chloroquine             | 2          |            |         |
| Sulfasalazine           | 11         |            |         |
| ACPA seropositive (n) (%) | | | |
| IgG (>10 U/mL)          | 29 (41.4)  | 0 (0)      | <0.000  |
| IgA (+2 SD above the mean of never-smoking healthy controls without periodontitis, n = 50) | | | |
| RF seropositive (n) (%) | | | |
| IgM (>5 IU/mL)          | 34 (48.6)  | 1 (1.4)    | <0.000  |
| IgA (>25 IU/mL)         | 25 (35.7)  | 0 (0)      | <0.000  |

RF: rheumatoid factor; Ig: immunoglobulin; NSAID: non-steroidal anti-inflammatory drug; DMARD: disease-modifying anti-inflammatory drug; † >2 SD above the mean of never-smoking healthy controls without periodontitis, n = 50.

The STROBE guidelines for human observational studies were followed. In short, RA patients were consecutively recruited at the outpatient Rheumatology Clinic, Sardjito Hospital, University of Gadjah Mada, in Yogyakarta, Indonesia. The inclusion criteria were in conformity with the 2010 RA classification criteria of the American College of Rheumatology (ACR) [2]. Exclusion criteria were: under 18 years of age, edentulism, diabetes, cardiovascular disease with anticoagulant medication, the presence of nonoral infection, antibiotic use <3 months prior to the study, the presence of malignancy, and pregnancy including a 6-month post-partum period, as well as breastfeeding. Consecutive NC were selected from patients with an appointment for a first consultation for a third molar assessment or tooth extraction at the Oral and Maxillofacial Surgery Clinic, Sardjito Hospital, or the Dental Hospital, Gadjah Mada University in Yogyakarta, Indonesia. Inclusion criteria for the NC were: not suffering from RA and the absence of any distinct oral pathology other than periodontitis. The same exclusion criteria were applied as for the RA patients. The subjects were matched according to age, sex, and smoking status. This study was reviewed and approved by the Medical and Health Research Ethics Committee of the Medical Faculty of Gadjah Mada University, Yogyakarta, Indonesia, according to the Declaration of Helsinki 2008 (Ref: KE/FK/430/EC). All the patients were informed verbally and by letter, and the participants provided written informed consent.
All periodontal measures and subgingival samplings were taken by the same examiner (PSR) who was calibrated by a periodontist (MJdS) that was trained in performing PISA and subgingival sampling.

2.2. Subgingival Microbial Sampling

Subgingival microbial samples were taken from the deepest bleeding site per quadrant based on pocket probing depth measurements. If there were no bleeding periodontal pockets, the mesial site of the first molar, or in the absence of the first molar, the mesial site from the adjacent anterior tooth in the dental arch, was selected. Sample sites were isolated with cotton rolls, and supragingival plaque was carefully removed with curettes and cotton pellets. Subsequently, 2 sterile paper points per site (Inline, BM Dentale, Turin, Italy) were inserted and left in place for 10 s. Paper points were pooled per patient and stored in a sterile microtube (Stardec, TG Medical SDN PHD) at $-20^\circ$C.

2.3. DNA Extraction and 16S rRNA Gene Sequencing

Three paper points of the microbial sample were added to 0.5 g of 0.1 mm zirconia beads (BioSpec Products Inc., Bartlesville, OK, USA) in 500 $\mu$L sterile phosphate-buffered saline and were beaten at 5.5 m/s for 3 $\times$ 1 min at room temperature (Precellys 24, Bertin Technologies, Montigny-le-Bretonneux, France). Hereafter, samples were heated at 95 $^\circ$C for 15 min and centrifuged at 4 $^\circ$C. The supernatant was collected, 2 $\mu$L of 10 mg/mL RNase H (Promega, Madison, WI, USA) was added, and it was incubated for 15 min at 37 $^\circ$C. Microbial DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer’s instructions. The purity and concentration of the DNA were measured with a NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). Illumina MiSeq preparation, and the sequencing and analysis of sequence reads were performed as described in Heida et al. [15]. For this study, the presence of Pg and Aa 16S rRNA was assessed. In short, the V3-V4 region of bacterial 16S rRNA genes was amplified by PCR with modified 341F and 806R primers containing a 6-nucleotide index sequence on the 806R primer [16]. FASTQ files of Illumina paired-end reads were processed with PANDAseq. The taxonomy of the phylum, family, and genus levels was determined using QIIME, and ARB was used to classify the bacteria at the species level [17–19]. Thereafter, the relative abundance of Pg and Aa was calculated by summing all counts of all species measured, and dividing the counts of each species with the sum of total counts, as percentages. For this study, we used the relative abundance for Pg an Aa only. A description of the entire microbiome is beyond the scope of this study.

2.4. Antibody Measurements in Serum

The IgG antibodies for Pg and Aa were measured by an in-house ELISA, in which pooled lysates of four randomly selected clinical isolates of Pg or Aa from patients with periodontitis were used as an antigen. Standard curves were made from protein standards (N protein-standard SL; Siemens Healthcare Diagnostics, Erlangen, Germany). The detection of anti-Pg and anti-Aa antibodies was carried out with mouse antihuman IgG (Fc fragment specific, clone JDC-10, Southern Biotech, Birmingham, AL 35209 USA). The variation coefficient was 20% [20].

The serum RA autoantibodies (ACPA and RF) were determined as described previously [13]. In short, IgG anticyclic citrullinated protein antibody (anti-CCP) levels were measured using a commercial anti-CCP2 kit (Euro Diagnostica, Arnhem, The Netherlands) according to the manufacturer’s protocol. Intra-assay variation was <10% and inter-assay variation was <12.5%. The IgA anti-CCP measurement was performed using a modification of the anti-CCP2 kit with goat antihuman IgA-HRP (Southern Biotech, Birmingham, Alabama 35209 USA), with a conjugate dilution of 1:4000 (10). The IgA seropositivity was defined as $>2$ SD above the mean of the never-smoking healthy controls without periodontitis in the present cohort, $n = 50$.
The RF IgM and IgA levels were determined using an in-house validated ELISA [21], and they are expressed in international units (IU) per milliliter. Inter- and intra-variation were <10%. Seropositivity was defined as >5 IU/mL for IgM RF, and >25 IU/mL for IgA RF.

2.5. Statistics

The major objective of our study was to evaluate to what extent serum antibodies against Pg and Aa in RA patients and the NC reflect the subgingival presence of Pg and Aa, and to assess whether antibodies against these two pathogens can be related to the severity of periodontal inflammation and the levels of serum autoantibodies specific for RA. Based on our own previous data [20,22], we calculated post hoc a statistical power of 98.8% in the difference of IgG anti-Pg antibody levels between a subgroup (n = 44) of non-RA individuals with (n = 19), and without (n = 25), cultivable subgingival Pg (Pg-negative mean 2.96 ±g/mL, SD 3.82, and Pg-positive mean 66.38 ±g/mL, SD 65.60, alpha 0.05; https://clincalc.com/stats/Power.aspx, accessed on 19 May 2021). Based on the literature, the prevalence of subgingival Pg is hardly different between RA and non-RA subjects and ranges from around 20% [20] to 80% [23]. Aiming for the inclusion of around 20 RA and 20 non-RA individuals positive for subgingival Pg, based on an estimated prevalence of 30% Pg positivity, we calculated that we required 67 individuals per group.

Statistical analyses were performed using GraphPad Prism software (version 8 for Windows; GraphPad Software). All data, except for age and DAS28, were non-normally distributed (based on QQ plots). For group comparisons, a Mann–Whitney U test was used for continuous variables, and a Fisher’s exact test was used for categorical variables. The correlations between different parameters were assessed by Spearman’s ρ. The significance level α was 0.05.

3. Results

3.1. Patients

The participant characteristics are listed in Table 1. Both cohorts were similar with regard to age, sex distribution, and smoking behavior. The median RA disease duration was 24 months, and 60% of the patient cohort presented high disease activity. The six patients using calcium channel blockers all had a low percentage of sites with bleeding on probing (range 0–9.4%).

A PISA value of ≥130 mm² has been shown to be associated with the case definition of periodontitis as defined by the Center for Disease Control and Prevention and the American Academy of Periodontology (CDC-AAP) [24]. The prevalence of periodontitis according to this cut-off was not significantly different between RA patients and the NC (Table 2). In the RA patients, there was no difference in the PISA between patients treated with DMARDs and those that were not (p = 0.908).

Subgingival Pg was detected in around 80% of the RA patients and the NC, while Aa tended to be more frequently detected in the NC than in RA patients. For details on periodontal characteristics, see Table 2.

Anti-Pg antibodies were detected in all sera, but the levels were significantly higher when subgingival Pg was identified. The same was observed for the levels of anti-Aa antibodies (Figure 1). No significant differences were observed between RA patients and the NC with regard to the levels of anti-P. gingivalis (Pg) and anti-A. actinomycetemcomitans (Aa) antibodies in relation to the presence or absence of periodontitis (PD) (Figure 2; anti-Pg: RA-non-PD: median 278 mg/L (IQR 106–606), RA-PD: 321 mg/L (41–459), NC-non-PD: 242 mg/L (102–534), NC-PD: 245 mg/L (74–1729). Anti-Aa: RA-non-PD: median 44 mg/L (IQR 24–74), RA-PD: 65 mg/L (21–105), NC-non-PD: 63 mg/L (33–125), NC-PD: 123 mg/L (47–262)).
### Table 2. Periodontal characteristics of patients with rheumatoid arthritis (RA) and non-RA controls (NC).

|                      | RA              | RA-nonPD        | RA-PD            | NC              | NC-nonPD        | NC-PD            | p Value |
|----------------------|-----------------|-----------------|------------------|-----------------|-----------------|------------------|---------|
| **N (%)**            | 70 (100)        | 55 (78.6)       | 15 (21.4)        | 70 (100)        | 53 (75.7)       | 17 (24.3)        | RA-NC   |
| **Number of teeth**  |                 |                 |                  |                 |                 |                  |         |
| (median, IQR)        | 26 (22–28)      | 26 (22–28)      | 26 (22–29)       | 27 (24–30)      | 28 (23–31)      | 27 (25–28)       | 0.072   |
| **PISA in mm²**      | 4.9 (0–1319)    | 0.3 (0–126)     | 304 (158–1319)   | 8.0 (0–1897)    | 0 (0–94)        | 509 (133–18,970) | 0.635   |
| **% of sites with pocket probing depth 1–2 mm** | 96 (74–99) | 56 (42–71) | 97 (94–99) | 93 (75–100) | 54 (34–63) | 97 (89–100) |         |
| (median, IQR)        | 4.7 (0.7–24.3)  | 41 (27–44)      | 2.3 (0.6–6.1)    | 5.6 (0–19.4)    | 37 (22–43)      | 2.1 (0–8.1)      |         |
| **% of sites with pocket probing depth 3–4 mm** | 4.7 (0.7–24.3) | 41 (27–44) | 2.3 (0.6–6.1) | 5.6 (0–19.4) | 37 (22–43) | 2.1 (0–8.1) |         |
| (median, IQR)        | 0 (0–0.8)       | 3.8 (1.1–13)    | 0 (0–0)          | 0 (0–2.6)       | 6.2 (2.0–23)    | 0 (0–0)          |         |
| **% of sites with bleeding on probing** | 1.1 (0–11) | 35 (18–57) | 0.6 (0–2.2) | 1.1 (0–10) | 30 (12–46) | 0 (0–2.8) |         |
| (median, IQR)        |                 |                 |                  |                 |                 |                  |         |
| **Periodontal pathogens detected:** | P. gingivalis (Pg) (n) (%) | 57 (81.4) | 45 (81.8) | 12 (80.0) | 55 (78.6) | 43 (81.1) | 13 (76.5) | 0.834 |
| A. actinomycetemcomitans (Aa) (n) (%) | 11 (15.7) | 9 (16.4) | 2 (13.3) | 21 (30.0) | 14 (26.4) | 7 (41.2) | 0.070 |
| Pg + Aa (n) (%)       | 10 (14.3)       | 8 (14.5)        | 2 (13.3)         | 19 (27.1)       | 12 (22.6)       | 7 (41.2)         | 0.094   |

PD: periodontitis, nonPD: no periodontitis. A PISA of ≥130 mm² has been shown to be associated with the CDC-AAP case definition of periodontitis [24].

**Figure 1.** Levels of anti-*P. gingivalis* (Pg) and anti-*A. actinomycetemcomitans* (Aa) antibodies in RA patients and non-RA controls (NC) positive or negative for these bacteria. Lines represent the median.
RA patients with no medication or treated only with herbal medication ($n = 8$) had higher anti-Aa levels compared to RA patients with medication ($p = 0.014$). Moreover, the levels of anti-Pg tended to be higher in RA patients without medication compared to RA patients with medication ($p = 0.066$, data not shown).

### 3.2. Correlations

The detection of subgingival Pg and Aa was highly correlated with the levels of anti-Pg and anti-Aa in RA patients ($\rho = 0.38$, $p < 0.001$ for Pg, $\rho = 0.29$, $p = 0.014$ for Aa) and in the NC ($\rho = 0.38$, $p = 0.001$ for Pg, $\rho = 0.29$, $p = 0.014$ for Aa) (Table 3). The average relative abundance of Pg was 1.966 (SD 4.439) for RA, and 2.558 (SD 4.969) for NC. The average relative abundance for Aa was 0.0632 (SD 0.360) for RA, and 0.3368 (SD 1.632) for NC.

### Table 3. Correlations (Spearman’s $\rho$) of anti-\textit{P. gingivalis} (Pg) and anti-\textit{A. actinomycetemcomitans} (Aa) antibodies with the subgingival relative abundance of Pg and Aa (number of sequences), periodontal inflamed surface area (PISA), and the RA autoantibodies ACPA and RF.

| Correlations                  | RA ($n = 70$) | NC ($n = 70$) |
|-------------------------------|--------------|---------------|
| with anti-Pg                  |              |               |
| Pg relative abundance         | 0.384        | 0.35          |
| PISA                          | −0.087       | 0.179         |
| ACPA IgG                      | 0.137        | −0.074        |
| ACPA IgA                      | 0.207        | −0.054        |
| RF IgM                        | 0.132        | −0.048        |
| RF IgA                        | 0.11         | 0.058         |
| with anti-Aa                  |              |               |
| Aa relative abundance         | 0.292        | 0.524         |
| PISA                          | −0.117       | 0.117         |
| ACPA IgG                      | 0.011        | 0.271         |
| ACPA IgA                      | −0.111       | 0.111         |
| RF IgM                        | 0.028        | 0.043         |
| RF IgA                        | 0.056        | 0.056         |

### 4. Discussion

In the present study, we showed that in both RA patients and the NC from an Indonesian cohort, the levels of serum anti-Pg and anti-Aa antibodies were associated with the detection of subgingival Pg and Aa. This implies that the measurement of antibodies against whole bacterial cell lysates of Pg or Aa is indicative of a subgingival Pg or Aa infection. As serum IgGs against Aa and Pg were previously shown to be extremely stable over 15 years in subjects with or without periodontitis; these levels indicate an infectious encounter with these pathogens at some point in time [25].
In our present cohort, the detection of subgingival Pg and Aa was comparable for RA patients and the NC, and the levels of anti-Pg and anti-Aa were comparable for RA patients and the NC at the group level. No noteworthy correlation was detected between antibodies against Pg and Aa- and RA-specific autoantibodies. In addition, antibodies against these two pathogens could not be related to the severity of periodontal inflammation. RA medication might influence anti-Pg and anti-Aa levels, although the group of RA patients without medication was small.

The prevalence of subgingival Pg in RA patients and the NC, and its possible relationships to antibodies or autoantibodies, has been investigated in several studies. However, no other group has investigated IgA antibodies, which are specific for mucosal immunity. In a previous study by our group, we observed that the subgingival prevalence of Pg was not different for the RA patients and the NC, and that there was no correlation detectable between the anti-Pg levels and arthritis autoantibodies in the serum [20]. Based on PCR analyses, Mikuls et al. [26] reported a 67% overall prevalence of subgingival Pg in RA patients, but this study did not address the possible correlations between subgingival Pg and ACPA and RF. Nevertheless, the authors reported a weak, but significant, correlation between the anti-Pg outer membrane antigen levels and ACPA (\(\rho = 0.14\)) and RF (\(\rho = 0.19\)) in RA patients (\(n = 287\)).

Schmickler et al. [27] showed by PCR that the prevalence of periodontal bacteria was not different for RA patients and the NC, but that higher numbers of Fusobacterium nucleatum and Pg were found in ACPA seropositive patients with RA. These different observations may relate to the use of different detection techniques and the inclusion of different patient groups. For instance, Scher et al. [23] analyzed the subgingival colonization of Pg by 16S rRNA pyrosequencing and identified Pg in 55% of patients with new-onset RA (without RA medication, \(n = 31\)), in 47% of patients with chronic RA (\(n = 34\)), and in 27% of healthy controls (\(n = 18\)). The difference in Pg prevalence could, however, be explained by the higher numbers of periodontitis cases in their RA population. When combining the findings from 16S rRNA pyrosequencing and/or a positive anti-Pg P18\(\gamma\) antibody response (against a chaperone peptide), the overall exposure to Pg was essentially the same for RA patients (78%) and the controls (83%), which is comparable to our present findings. Thus, it appears from both this study and ours that, overall, the exposure to Pg is relatively high in patients with and without (present) periodontitis.

The subgingival prevalence of Pg in a Norwegian cohort of 78 established RA patients was 22%, which is much lower than observed in the present study, although the same sequencing techniques were used [28]. Nonetheless, similar to our findings, no correlation of Pg with ACPA or RF in the serum of RA patients was detected. Furthermore, a recent meta-analysis showed that anti-Pg antibodies were positively correlated with RF and ACPA in RA patients, but the correlation coefficients were low (0.07 for RF, 0.15 for ACPA) [29]. Lastly, Konig et al. [10] investigated antibodies against the leukotoxin LtxA of Aa in RA patients and reported an association of anti-LtxA with ACPA and RF. However, it seems likely that the anti-LtxA levels are more representative for subgingival Aa infection [30], as there was no particular association with RA, with ACPA, or with the HLA SE alleles, which are the most important genetic risk factors for RA [10].

This study has some limitations. As radiographic assessment is necessary to confirm a periodontal diagnosis, the PISA in our study does not necessarily reflect the periodontal diagnosis, but the inflammatory burden. Therefore, the division of the presence or absence of periodontitis according to the cut-off is somewhat artificial. Furthermore, the prevalence of periodontitis according to the PISA was relatively low in our groups, but this is a common finding amongst women in Indonesia [31]. In the latter study, the burden of periodontitis was also comparable amongst RA patients and the matched NC. The vast majority of the cohort of this study was female (88%). The cohort was of Indonesian descent and, in this country, women usually do not smoke. An explanation for the lower values of ACPA might be the extremely low number of smoking RA patients, as smoking has been shown to be associated with an increased risk in ACPA-positive RA in the Malaysian population, which
is geographically closely related to the Indonesian population [32]. Despite antirheumatic treatment, the majority of the RA patients had high RA disease activity. This might be due to the limited access to biological treatment for many patients in Indonesia because of the high costs [33]. Antirheumatic treatment seems to have a negligible influence on the periodontal condition of RA patients, and to not have an influence on the subgingival presence of Pg and Aa, accordingly [34,35].

5. Conclusions
The present study shows that, in our Indonesian cohort, antibody levels against whole bacterial cell lysates of Pg or Aa reflect subgingival infection by Pg or Aa, which was equally prevalent in RA patients and the non-RA controls. Importantly, no evidence for an association of antibodies against these periodontal pathogens and RA-specific autoantibodies was detected. Thus, it seems that the levels of antibodies against these two oral pathogens have no predictive value for arthritis development, as has been shown by our group for anti-Pg in clinically suspect arthralgia patients [22,36].

Author Contributions: Conceptualization, M.J.d.S., J.M.v.D., A.V. and J.W.; methodology, M.J.d.S., J.M.v.D., A.V. and J.W.; validation, M.J.d.S., E.R.-E., M.d.T.E., T.S. and P.L.; formal analysis, P.S.R., M.d.T.E., E.R.-E., T.S. and P.L.; investigation, P.S.R. and M.J.d.S.; resources, A.V. and J.W.; data curation, M.J.d.S.; writing—original draft preparation, P.S.R. and M.J.d.S.; writing—review and editing; M.J.d.S., T.S., H.J.M.H., J.M.v.D., N.K., A.V. and J.W.; visualization, M.J.d.S. and J.W.; supervision, H.J.M.H., J.M.v.D., N.K., A.V. and J.W.; project administration, A.V. and J.W.; funding acquisition, A.V. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the author’s institutions, and partly by the Dutch Arthritis Foundation (ReumaNederland, grant number 16-2-201), as well as an Abel Tasman Talent Program sandwich Ph.D. grant from the Graduate School of Medical Sciences of the University of Groningen. All authors have reported no conflicts of interest.

Institutional Review Board Statement: This study was reviewed and approved by the Medical and Health Research Ethics Committee of the Medical Faculty of Gadjah Mada University, Yogyakarta, Indonesia, according to the Declaration of Helsinki 2008 (Ref: KE/FK/430/EC, 29 April 2014).

Informed Consent Statement: All the patients were informed verbally and by letter, and the participants provided written informed consent.

Data Availability Statement: Data are available through the second author of the study.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References
1. Lopez-Oliva, I.; De Pablo, P.; Dietrich, T.; Chapple, I. Gums and joints: Is there a connection? Part one: Epidemiological and clinical links. Br. Dent. J. 2019, 227, 605–609. [CrossRef]
2. Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.; Bingham, C.O., III; Birnbaum, G.R.; Bykerk, V.P.; Cohen, M.D. et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581. [CrossRef] [PubMed]
3. Rosenstein, E.D.; Greenwald, R.A.; Kushner, L.J.; Weissmann, G. Hypothesis: The Humoral Immune Response to Oral Bacteria Provides a Stimulus for the Development of Rheumatoid Arthritis. Inflammation 2004, 28, 311–318. [CrossRef] [PubMed]
4. Lundberg, K.; Wegner, N.; Yucei-Lindberg, T.; Venables, P.J. Periodontitis in RA—the citrullinated enolase connection. Nat. Rev. Rheumatol. 2010, 6, 727–730. [CrossRef]
5. Catrina, A.I.; Deane, K.D.; Scher, J.U. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology 2016, 55, 391–402. [CrossRef]
6. Wegner, N.; Wait, R.; Sroka, A.; Eick, S.; Nguyen, K.-A.; Lundberg, K.; Kinloch, A.; Culshaw, S.; Potempa, J.; Venables, P.J. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010, 62, 2662–2672. [CrossRef] [PubMed]
7. Stobernack, T.; Espina, M.D.T.; Mulder, L.M.; Medina, L.M.P.; Piebenga, D.R.; Gabarrini, G.; Zhao, X.; Janssen, K.M.J.; Hulzebos, J.; Brouwer, E.; et al. A Secreted Bacterial Peptidylarginine Deiminase Can Neutralize Human Innate Immune Defenses. MBio 2018, 9, e01704-18. [CrossRef]
8. Gabarrini, G.; Grasso, S.; van Winkelhoff, A.J.; van Dijl, J.M. Gingimap: Protein Localization in the Oral Pathogen Porphyromonas gingivalis. Microbiol. Mol. Biol. Rev. 2020, 84, e00352-19. [CrossRef]

9. Potempa, J.; Mydel, P.; Koziel, J. The case for periodontitis in the pathogenesis of rheumatoid arthritis. Nat. Rev. Rheumatol. 2017, 13, 606–620. [CrossRef] [PubMed]

10. Konig, M.F.; Abusleme, L.; Reinholdt, J.; Palmer, R.J.; Teles, R.P.; Sampson, K.; Rosen, A.; Nigrovic, P.A.; Sokolove, J.; Giles, J.T.; et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci. Transl. Med. 2016, 8, 369ra176. [CrossRef]

11. Ferreira, R.D.O.; Silva, R.D.B.; Magno, M.B.; Almeida, A.P.C.P.S.C.; Fagundes, N.C.F.; Maia, L.; Lima, R.R. Does periodontitis represent a risk factor for rheumatoid arthritis? A systematic review and meta-analysis. Ther. Adv. Musculoskelet. Dis. 2019, 11. [CrossRef]

12. Johansson, L.; Sherina, N.; Kharlamova, N.; Potempa, B.; Larsson, B.; Israelsson, L.; Potempa, J.; Rantapää-Dahlqvist, S.; Lundberg, K. Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis. Arthritis Res. 2016, 18, 201. [CrossRef]

13. Rahajoe, P.S.; De Smit, M.; Schuurmans, G.; Raveling-Eelsing, E.; Kertia, N.; Vissink, A.; Westra, J. Increased IgA anti-citrullinated protein antibodies in the periodontal inflammatory exudate of healthy individuals compared to rheumatoid arthritis patients. J. Clin. Periodontol. 2020, 47, 552–560. [CrossRef]

14. Nesse, W.; Abbas, F.; Van Der Ploeg, I.; Spijkervet, F.K.L.; Dijkstra, P.U.; Vissink, A. Periodontal inflamed surface area: Quantifying inflammatory burden. J. Clin. Periodontol. 2008, 35, 668–673. [CrossRef] [PubMed]

15. Heida, F.H.; Van Zoonen, A.G.J.F.; Hulscher, J.B.F.; Kiefte, B.J.C.T.; Wessels, R.; Kooi, E.M.W.; Bos, A.F.; Harmsen, H.J.M.; de Goffau, M. A Nectrotizing Enterocolitis-Associated Gut Microbiota Is Present in the Meconium: Results of a Prospective Study. Clin. Infect. Dis. 2016, 62, 863–870. [CrossRef]

16. Bartram, A.K.; Lynch, M.D.J.; Stearns, J.C.; Moreno-Hagelsieb, G.; Neufeld, J.D. Generation of Multimillion-Sequence 16S rRNA Gene Libraries from Complex Microbial Communities by Assembling Paired-End Illumina Reads. Appl. Environ. Microbiol. 2011, 77, 3846–3852. [CrossRef]

17. Ludwig, W.; Strunk, O.; Westram, R.; Richter, L.; Meier, H.; Yadhukumar, A.; Buchner, A.; Lai, T.; Steppi, S.; Jobb, G.; et al. ARB: A software environment for sequence data. Nucleic Acids Res. 2004, 32, 1363–1371. [CrossRef] [PubMed]

18. Masella, A.P.; Bartram, A.K.; Truszkowski, J.M.; Brown, D.G.; Neufeld, J.D. PANDAseq: Paired-end assembler for illumina sequences. BMC Bioinform. 2012, 13, 31. [CrossRef] [PubMed]

19. Veloo, A.; Elgersma, P.; Friedrich, A.; Nagy, E.; van Winkelhoff, A. The influence of incubation time, sample preparation and exposure to oxygen on the quality of the MALDI-TOF MS spectrum of anaerobic bacteria. Clin. Microbiol. Infect. 2014, 20, O1091–O1097. [CrossRef] [PubMed]

20. De Smit, M.; Westra, J.; Vissink, A.; Der Meer, B.D.-V.; Brouwer, E.; Van Winkelhoff, A.J. Periodontitis in established rheumatoid arthritis patients: A cross-sectional clinical, microbiological and serological study. Arthritis Res. Ther. 2012, 14, R222. [CrossRef]

21. Van Leeuwen, M.A.; Westra, J.; Van Riel, P.; Limburg, P.C.; Van Rijswijk, M.H. IgM, IgA, and IgG Rheumatoid Factors in Early Population-based Cohort (Lifelines). Z. Rheumatol. 2017, 76, 195–198. [CrossRef]

22. Westra, J.; Brouwer, E.; Raveling-Eelsing, E.; Arends, S.; Abdulle, A.E.; Roodendaal, C.; Delft, M.A.M.V.; Toes, R.E.M.; Trouw, L.A.; Vissink, A.; et al. Arthritis autoantibodies in individuals without rheumatoid arthritis: Follow-up data from a Dutch population-based cohort (Lifelines). Rheumatology 2020, 60, 658–666. [CrossRef] [PubMed]

23. Scher, J.U.; Ubeda, C.; Equinda, M.; Khanin, R.; Buischer, Y.; Viale, A.; Lipuma, L.; Attur, M.; Pillinger, M.; Weissmann, G.; et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Rheumatology 2012, 46, 3083–3094. [CrossRef] [PubMed]

24. Leira, Y.; Martin-Lancharrro, P.; Blanco, J. Periodontal inflamed surface area and periodontal case definition classification. Acta Odontol. Scand. 2017, 76, 195–198. [CrossRef]

25. Mak, T.; Ansell, G.; Pui, S.; Kinney, M.; Pugsley, T.; Althoff, G. Tracking of plasma antibodies against Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis during 15 years. J. Oral Microbiol. 2009, 1, 1979. [CrossRef] [PubMed]

26. Mikuls, T.R.; Payne, J.; Yu, F.; Thiele, G.; Reynolds, R.J.; Cannon, G.W.; Markt, J.; McGowan, D.; Kerr, G.S.; Redman, R.S.; et al. Periodontitis and Porphyromonas gingivalis Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2014, 66, 1090–1100. [CrossRef] [PubMed]

27. Schmickler, J.; Rupprech, A.; Patschan, S.; Patschan, D.; Muller, G.A.; Haak, R.; Mausbach, G.F.; Schmalz, G.; Kottmann, T.; Ziebolz, D. Cross-Sectional Evaluation of Periodontal Status and Microbiologic and Rheumatoid Parameters in a Large Cohort of Patients with Rheumatoid Arthritis. J. Periodontol. 2017, 88, 368–379. [CrossRef]

28. Beyer, K.; Zaura, E.; Brandt, B.W.; Buijs, M.J.; Brun, J.G.; Crielard, W.; Bolstad, A.I. Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health. PLoS ONE 2018, 13, e0202278. [CrossRef]

29. Bae, S.C.; Lee, Y.H. Association between anti-Porphyromonas gingivalis antibody, anti-citrullinated protein antibodies, and rheumatoid arthritis. Z. Rheumatol. 2017, 77, 522–532. [CrossRef]

30. Volkov, M.; Dekkers, J.; Loos, B.G.; Bizzarro, S.; Huizinga, T.W.J.; Praetorius, H.A.; Toes, R.; Van Der Woude, D. Comment on “Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis”. Sci. Transl. Med. 2018, 10, eaan8349. [CrossRef]
31. Susanto, H.; Nesse, W.; Kertia, N.; Soeroso, J.; Van Reenen, Y.H.; Hoedemaker, E.; Agustina, D.; Vissink, A.; Abbas, F.; Dijkstra, P.U. Prevalence and Severity of Periodontitis in Indonesian Patients with Rheumatoid Arthritis. *J. Periodontol.* 2013, 84, 1067–1074. [CrossRef] [PubMed]

32. Yahya, A.; Bengtsson, C.; Lai, T.C.; Larsson, P.T.; Mustafa, A.N.; Abdullah, N.A.; Muhamad, N.; Hussein, H.; Klareskog, L.; Alfredsson, L.; et al. Smoking is associated with an increased risk of developing ACPA-positive but not ACPA-negative rheumatoid arthritis in Asian populations: Evidence from the Malaysian My EIRA case–control study. *Mod. Rheumatol.* 2011, 22, 524–531. [CrossRef] [PubMed]

33. Fia, F.; Westra, J. Overview of rheumatoid arthritis therapy: Management options in Indonesia. *Tarumanagara Med. J.* 2018, 1, 208–220.

34. Äyräväinen, L.; Leirisalo-Repo, M.; Kuuliala, A.; Ahola, K.; Koivuniemi, R.; Meurman, J.H.; Heikkinen, A.M. Periodontitis in early and chronic rheumatoid arthritis: A prospective follow-up study in Finnish population. *BMJ Open* 2017, 7, e011916. [CrossRef]

35. De Smit, M.; Westra, J.; Posthumus, M.; Springer, G.; van Winkelhoff, A.; Vissink, A.; Brouwer, E.; Bijl, M. Effect of Anti-Rheumatic Treatment on the Periodontal Condition of Rheumatoid Arthritis Patients. *Int. J. Environ. Res. Public Health* 2021, 18, 2529. [CrossRef]

36. De Smit, M.; Van De Stadt, L.A.; Janssen, K.M.J.; Der Meer, B.D.-V.; Vissink, A.; Van Winkelhoff, A.J.; Brouwer, E.; Westra, J.; Van Schaardenburg, D. Antibodies against *Porphyromonas gingivalis* seropositive arthralgia patients do not predict development of rheumatoid arthritis. *Ann. Rheum. Dis.* 2014, 73, 1277–1279. [CrossRef]